@article{f8a58ff2cfd64b36a76d0af67e838d5c,
title = "The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation",
abstract = " Background: The 12-item Concise Health Risk Tracking Self-Report (CHRT-SR 12 ) is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. It can be used as a tool to both assess risk and guide treatment interventions targeting associated cognitions. Methods: This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine. Outcome assessors and patients were masked to treatment. Results: Factor analysis of CHRT-SR 12 confirmed that the 12 items have higher order structure with two subscales (Propensity, Suicidal Thoughts) and a total score. Internal consistencies were acceptable for both subscales and total score. All three scales were modestly correlated with overall depression severity (r = 0.54 to r = 0.21) and highly discriminating among patients grouped by suicide item ratings on three different depressive symptom ratings. The three scales also distinguished change over the acute phase treatment for those with different levels of baseline suicidal ideation (measured by 30-item Inventory of Depressive Symptomatology (item 18) and for those with change in suicidal ideation (baseline to last visit). Conclusions: The CHRT-SR 12 has good to excellent psychometric properties and is sensitive to change in suicidal thinking and propensity toward suicidal behavior in outpatients with major depressive disorder. It allows for the monitoring of thoughts and feelings associated with increased suicidal risk as well as levels of thoughts about suicide.",
keywords = "Concise Health Risk Tracking Scale (CHRT-SR), depression, psychometrics, suicidal ideation, suicidality, suicide risk",
author = "{De La Garza}, Nancy and Rush, {A. John} and Killian, {Michael O.} and Grannemann, {Bruce D.} and Carmody, {Thomas J} and Trivedi, {Madhukar H}",
note = "Funding Information: The authors would like to thank Jeremy A. Kee, for his editorial and administrative support. To obtain a copy of the CHRT, please contact the corresponding author, Dr. Madhukar Trivedi. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Concise Health Risk Tracking Self-Report is copyrighted by the University of Texas Southwestern Medical Center. To access the CHRT-SR, please contact Dr. Madhukar Trivedi at madhukar.trivedi@utsouthwestern.edu. Funding Information: A. John Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Eli Lilly, Emmes Corp, Liva-Nova, Mind Linc., Sunovion, Takeda USA, Taj Medical; speaking fees from Liva-Nova and Sing-Health; and royalties from Guil-ford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named coinventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Trivedi has received consulting fees from Alkeremes Inc., Otsuka America Pharmaceutical Inc., Lundbeck Research USA, Medscape, One Carbon Therapeutics, Pfizer Inc., Takeda Global Research, Allergan Pharmaceuticals, Lilly Research Laboratories, Merck & Co. Inc., Sunovion Pharmaceuticals, Inc., and Avanir Pharmaceuticals. He has received honoraria from the America Psychiatric Association. He has also received grants from the National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA), National Center for Advancing Translational Sciences (NCATS), Cancer Prevention and Research Institute of Texas (CPRIT), PCORI, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Agency for Healthcare Research and Quality (AHRQ), and Johnson & Johnson. Drs. Garza, Killian, and Carmody, and Mr. Grannemann have no financial relationships to disclose. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = apr,
doi = "10.1002/da.22855",
language = "English (US)",
volume = "36",
pages = "313--320",
journal = "Depression and anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "4",
}